Carnitine Palmitoyltransferase II Deficiency
An inherited disorder of long-chain fatty acid metabolism, ranging from a severe neonatal presentation to a myopathic adult form marked by exercise-induced muscle breakdown.
- Fatty Acid Oxidation Disorder
- Autosomal Recessive (CPT2 Gene)
- Managed with Diet & Activity Modification
- Most Common Form
- Myopathic (Adult-Onset)
- Inheritance Pattern
- Autosomal Recessive
- Gene Involved
- CPT2
- Management Anchor
- Avoid Fasting & Manage Triggers
Condition Overview
Carnitine palmitoyltransferase II (CPT II) deficiency is an inherited disorder affecting the transport and breakdown of long-chain fatty acids inside mitochondria. CPT II is required for fatty acids to enter the mitochondrial matrix for energy production, particularly during fasting, prolonged exercise, or illness when the body relies more heavily on fat metabolism.
The condition spans a wide clinical spectrum. The myopathic form, most common in adolescents and adults, causes episodes of exercise-induced muscle pain and rhabdomyolysis but is otherwise compatible with a largely normal life between episodes. Severe infantile and lethal neonatal forms affect multiple organs, including the liver, heart, and brain, and require intensive management.
Recognizing the diagnosis allows patients to avoid known triggers and intervene early when symptoms occur, substantially reducing complication risk.
Types and Subtypes
CPT II deficiency is classified into three main clinical forms based on age of onset and severity.
Symptoms and Signs
Symptoms vary considerably by form, with the myopathic type generally limited to episodic muscle-related symptoms.
Causes and Risk Factors
CPT II deficiency is caused by biallelic pathogenic variants in the CPT2 gene, which encodes the enzyme responsible for converting acylcarnitines back to acyl-CoA inside mitochondria.
Diagnosis and Investigations
Diagnosis combines biochemical screening, enzyme studies, and genetic confirmation.
Disease Classification and Risk Stratification
CPT II deficiency does not use tumor-style staging; risk is instead stratified by clinical subtype, which correlates with severity and monitoring needs.
Standard Treatment Options
Treatment focuses on avoiding metabolic triggers, dietary modification, and prompt management of acute episodes.
Advanced and Emerging Approaches
Most management remains dietary and preventive; research is exploring additional pharmacologic and genetic strategies.
Precision Medicine
Genotype-Informed Risk Stratification
Genetic findings increasingly help predict phenotype severity and tailor monitoring intensity.
Investigational Pharmacotherapy
Triheptanoin and Related Anaplerotic Therapies
Specialized medium-chain triglyceride formulations are being studied as adjuncts to standard dietary management in fatty acid oxidation disorders.
Biomarkers and Laboratory Monitoring
Laboratory markers help confirm diagnosis and monitor for episodes rather than guide a staging decision.
When a Second Opinion May Be Important
Specialist input is valuable for confirming diagnosis and individualizing management, especially in less common presentations.
Clinical Trials and Research
Outlook and Key Outcome Factors
Outlook varies widely by clinical subtype, with the myopathic adult-onset form generally compatible with a normal lifespan when triggers are managed.
Supportive Care and Living with CPT II Deficiency
Ongoing care focuses on lifestyle adaptation, monitoring, and preparedness for acute episodes.
How CancerFax Helps You Explore Treatment Options
CancerFax can help patients and families coordinate medical report review, connect with metabolic specialists for second opinions, and identify experienced centers for ongoing monitoring of CPT II deficiency.
Get a free case reviewFrequently Asked Questions
It is an inherited disorder of fatty acid metabolism that impairs the body's ability to use long-chain fats for energy, particularly during fasting or prolonged exercise.
It is caused by inherited pathogenic variants in the CPT2 gene, passed down in an autosomal recessive pattern from two carrier parents.
The most common myopathic form causes episodes of exercise-induced muscle pain, weakness, and dark urine from muscle breakdown.
Diagnosis combines an abnormal acylcarnitine profile, enzyme testing, and genetic confirmation of CPT2 gene variants.
Yes, primarily through trigger avoidance, dietary adjustments, and prompt treatment of acute episodes; severe infantile forms require more intensive management.
Episodes of rhabdomyolysis can cause acute kidney injury if untreated, but between episodes most patients with the myopathic form are otherwise healthy.
Yes, severe infantile and lethal neonatal forms exist and involve multiple organs, including the liver and heart.
Parents of an affected child are carriers, with an approximate 25% recurrence risk in future pregnancies; genetic counseling is recommended.
No, it is a fatty acid metabolism disorder and is not associated with increased cancer risk.
Yes. CancerFax can help coordinate medical report review, facilitate second opinions with metabolic specialists, and assist with matching patients to experienced centers for ongoing care.
Get Expert Guidance for CPT II Deficiency
CancerFax can help connect you with metabolic specialists, support second opinions, and guide you through ongoing management decisions.